Cost-effectiveness of gilteritinib for relapsed/ refractory FLT3mut+ acute myeloid leukemia

Cost-effectiveness of gilteritinib for relapsed/ refractory FLT3mut+ acute myeloid leukemia

BACKGROUND: Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and confirmed feline McDonough sarcoma (FMS)-like tyrosine kinase 3 gene mutations (FLT3mut+) have a poor prognosis and limited effective treatment options. Gilteritinib is the first targeted therapy approved in the...

Full description

Bibliographic Details
Main Authors: Garnham, A. (Author), Pandya, B.J (Author), Qi, C.Z (Author), Shah, M.V (Author), Yang, H. (Author), Zeidan, A.M (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
acute myeloid leukemia
adult
adverse event
aged
Aniline Compounds
aniline derivative
Article
azacitidine
CD135 antigen
controlled study
cost benefit analysis
cost effectiveness analysis
Cost-Benefit Analysis
cytarabine
economics
etoposide
event free survival
FLT3 protein, human
fludarabine
fms-Like Tyrosine Kinase 3
gene mutation
genetics
gilteritinib
granulocyte colony stimulating factor
health status
hematopoietic stem cell transplantation
hospitalization cost
human
Humans
idarubicin
leukemia relapse
leukemia remission
Leukemia, Myeloid, Acute
long term survival
low drug dose
middle aged
mitoxantrone
mortality rate
overall survival
palliative chemotherapy
pyrazine derivative
Pyrazines
quality adjusted life year
Quality-Adjusted Life Years
Recurrence
recurrent disease
survival analysis
Survival Analysis
survival rate
treatment outcome
United States
Willingness To Pay
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items